Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review found that while topical minoxidil is effective for treating female pattern hair loss, finasteride showed no more effectiveness than placebo, and low-level laser therapy increased hair count but with inconsistent results.

Over 40% of postmenopausal women experience hair loss, with treatments aiming to stop further loss and possibly thicken hair.

This article reviews treatment options for male-pattern and female-pattern hair loss, telogen effluvium, and alopecia areata, but provides no new clinical results; algorithmic management approaches are included.

This review discusses the development of an algorithmic guideline for treating androgenetic alopecia in Asian patients, using the BASP classification to address limitations of previous guidelines, and reports no clinical results.

This review discusses the safety concerns associated with new treatments for non-scarring alopecias, highlighting that while these therapies such as JAK inhibitors and oral minoxidil show efficacy in hair regrowth, their safety profiles vary significantly, requiring careful consideration of benefits and risks.

In this clinical experience, treating frontal fibrosing alopecia with oral finasteride, hydroxychloroquine, tacrolimus, and excimer laser was associated with optimal results in patients with active inflammation.

This article reviews treatment options for male androgenetic alopecia, including their distinct aims of arresting progression, stimulating regrowth, and concealing hair loss, and reports no new clinical results.

This consensus from the Taiwanese Dermatological Association suggests that for mild to moderate alopecia areata, first-line treatments may include topical or intralesional corticosteroids, possibly with topical minoxidil, while severe cases might require systemic corticosteroids or Janus kinase inhibitors.

This review discusses treatment options for androgenetic alopecia, with a focus on the better efficacy of oral finasteride and dutasteride over topical minoxidil for male pattern hair loss, but it reports no new clinical results.

This review covers androgenetic alopecia's epidemiology, pathogenesis, current management options, and research trends, concluding that no definitive cure exists despite extensive interest and ongoing genetic research efforts.

In this narrative review, researchers reported that oral finasteride significantly improved hair count and density in male androgenetic alopecia but had higher systemic exposure and potential side effects compared to topical formulations, which provided similar efficacy with lower systemic DHT suppression.

This expert panel review developed consensus recommendations for managing androgenetic alopecia in Canadian adults, endorsing seven interventions like oral and topical medications and platelet-rich plasma.

This study discusses treatment options for androgenetic alopecia, highlighting that while available therapies include approved and off-label pharmacological agents and non-pharmacological treatments, there is still limited evidence-based guidance on managing this common hair loss disorder.

This study found that postmenopausal women in Argentina with frontal fibrosing alopecia had a higher average age of diagnosis than previously reported, with similar clinical features to international cases.

This review found that intralesional corticosteroid injections and 5-alpha-reductase inhibitors were reported as the most effective treatments for frontal fibrosing alopecia, with oral isotretinoin showing promise for facial papule improvement.

This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.

This review discusses clinical features, differential diagnosis, and treatments for female pattern hair loss, emphasizing the use of 2% topical Minoxidil and exploring alternative off-label therapies.

This review highlights current treatment options for frontal fibrosing alopecia, noting that 5-α-reductase inhibitors, intralesional steroids, and hydroxychloroquine have the highest evidence of effectiveness, while other therapies show variable results and need further research.

This research suggests that recent discoveries of signaling pathways in androgenic alopecia may pave the way for targeted therapies, providing potential new treatment options beyond the current FDA-approved drugs, minoxidil and finasteride.

This review of female androgenetic alopecia treatments reports limited therapeutic options due to unclear pathogenesis, with minoxidil as the only FDA-approved treatment and adjuvant therapies under investigation.

This paper outlines that treatments reducing estrogen for estrogen receptor-positive breast cancer, such as SERMs and AIs, significantly improve life expectancy but may lead to alopecia in 15% to 25% of patients.

The NAMS 2014 recommendations guide healthcare providers on treating health issues in midlife women, emphasizing individualized care and informed decision-making.

This article discusses the evaluation and management of a 45-year-old woman with diffuse scalp-hair loss and reports no new clinical findings.

This article reviews recent advancements in understanding and treating androgenetic alopecia, focusing on new genetic insights, stem cell roles, and diagnostic tools, without reporting new clinical results.

This review discusses the dermatologic manifestations of hyperandrogenism in women and outlines the diagnostic approach and treatment options, reporting no new clinical results.

This review discusses the potential causes and treatments for frontal fibrosing alopecia but reports no new clinical findings, highlighting the need for further research to understand its pathogenesis and develop validated treatments.

This review discusses treatment options for female pattern hair loss, emphasizing the importance of early intervention and the benefits of combined therapies, but reports no new clinical results.

This review discusses the physiology and potential hormonal mechanisms involved in female pattern hair loss, as well as the current hormonal and hormone-modifying treatments available, but reports no new research findings.

This study found that Sargassum muticum extract and apo-9′-fucoxanthinone promoted hair growth in rat and mouse models by increasing dermal papilla cell proliferation and activating certain signaling pathways.

This review provides an overview of caffeine's effects on cancer, cardiovascular, immunological, inflammatory, and neurological diseases, highlighting both its potential benefits, such as neuroprotection and anti-aging, and possible adverse effects like elevated blood pressure, anemia, and migraine.